Over the past few years, China has been offering AstraZeneca bragging rights. But the company's business in the country is coming to a turning point after being exposed to the government's price-cutting scheme and local competition—and investors have caught wind. During a conference call Thursday, Wall Street analysts piled into AstraZeneca's China performance, pressing management on whether the company can sustain its double-digit sales growth in the country. The short answer? Expect slower growth going forward. "Slower growth in China is no question," AstraZeneca CEO Pascal Soriot told investors on the call.